论文部分内容阅读
肺癌是全球最常见的恶性肿瘤,是全世界癌症相关死亡的主要原因。LncRNA是指一类至少包含200个核苷酸且不具有编码蛋白质功能的RNA。许多lnc RNA都具有促进或抑制NSCLC发展及恶化的功能。由于其调节基因表达方面的基础作用,连同其在肿瘤生成的生物学机制,它们是一类有前途的组织或血液生物标志物。本文我们强调lnc RNA在NSCLC的新兴作用,并讨论其作为诊断和预后的生物标志物及治疗靶点的潜在临床应用。
Lung cancer is the most common malignancy in the world and is the leading cause of cancer-related deaths worldwide. LncRNA refers to a class of RNA that contains at least 200 nucleotides and does not have a protein-encoding function. Many lnc RNAs have the function of promoting or inhibiting the development and worsening of NSCLC. They are a promising class of tissue or blood biomarkers because of their fundamental role in regulating gene expression, along with their biological mechanisms in tumorigenesis. Here we highlight the emerging role of lnc RNA in NSCLC and discuss its potential clinical use as a biomarker and therapeutic target for diagnosis and prognosis.